Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Apogee Therapeutics ( (APGE) ) has shared an update.
On October 8, 2025, Apogee Therapeutics entered into an underwriting agreement to issue and sell shares and pre-funded warrants, raising approximately $323.3 million. The offering is expected to close on October 10, 2025. The company also updated its clinical trial milestones, with increased patient enrollment for its APEX Phase 2 trial and expected data reports in 2026 for both atopic dermatitis and asthma trials.
The most recent analyst rating on (APGE) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Apogee Therapeutics stock, see the APGE Stock Forecast page.
Spark’s Take on APGE Stock
According to Spark, TipRanks’ AI Analyst, APGE is a Neutral.
The overall score reflects the company’s early-stage biotech position, with significant financial risks due to no revenue and high cash burn. Positive clinical trial results and a strong cash position are key strengths, but valuation concerns and technical analysis suggest caution.
To see Spark’s full report on APGE stock, click here.
More about Apogee Therapeutics
Apogee Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for atopic dermatitis and asthma. The company is engaged in clinical trials to advance its product pipeline, including the APEX Phase 2 trial of APG777 for atopic dermatitis and a Phase 1b trial for asthma.
Average Trading Volume: 623,374
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.82B
See more data about APGE stock on TipRanks’ Stock Analysis page.